Anelixis Therapeutics - Ownership and Business Overview

Life ScienceCompany

Anelixis Therapeutics Ownership

Who owns Anelixis Therapeutics?

Anelixis Therapeutics is owned by Eledon Pharmaceuticals. It was acquired on September 14, 2020.

Anelixis Therapeutics Business Overview

Where is Anelixis Therapeutics headquartered?

Anelixis Therapeutics is headquartered in Cambridge, Massachusetts.

What sector is Anelixis Therapeutics in?

Anelixis Therapeutics is a life science company.

When was Anelixis Therapeutics founded?

Anelixis Therapeutics was founded in 2012.

Life Science M&A Summary in 2020

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2020. The largest life science acquisition in 2020 was Alexion Pharmaceuticals - which was acquired by AstraZeneca for $39.0B.

Join Mergr to view all 290 acquisitions of life science companies in 2020, including 23 acquisitions by private equity firms, and 267 by strategics.

Anelixis Therapeutics, Inc.

300 Technology Square, Suite 400,
Cambridge, Massachusetts 02139
United States,
www.anelixistherapeutics.com

Anelixis Therapeutics, Inc. is a privately held clinical stage biotechnology company developing a next generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. Anelixis Therapeutics was founded in 2012 and is based in Cambridge, Massachusetts.


 Subscribe to unlock this and 208,848
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 204K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.